







Lamotrigine as a treatment for prevention of recurrence of bipolar disorder, Review question, To investigate the clinical effectiveness (benefits and harms) of lamotrigine for maintenance therapy of bipolar disorder in comparison with placebo, combination therapy or existing drugs (e.g. lithium, olanzapine)., Background, Lamotrigine is approved for the maintenance treatment (treatment for prevention of recurrence) of bipolar disorder. It could be a viable and effective treatment strategy for the maintenance of bipolar disorder, where it demonstrated a lower risk of recurrence than placebo. In addition, it has been reported to be as effective as lithium. Therefore, we performed a systematic review to investigate the efficacy and safety of lamotrigine in the maintenance treatment (treatment for prevention of recurrence) of bipolar disorder., Key findings, The evidence is current to May 2021. We included 11 studies in this review with a total 2314 participants. 1146 participants were assigned to lamotrigine, and 1168 participants were assigned to control intervention (869 received placebo and 299 received lithium)., Our review identified the following., Lamotrigine versus placebo, Benefits: lamotrigine was found to be superior over placebo in the following outcomes., 1) Reduced the rate of recurrence of manic symptoms , 2) Suppressed depressive symptoms, 3) Less need for additional therapeutic agents for the recurrence of all symptoms, 4) Reduction in the withdrawal rate due to any causes six months or more after the initiating of intervention, Harms: adverse‐event profile of lamotrigine was similar to that of placebo., Lamotrigine versus lithium, Benefits: lamotrigine was as effective as lithium, except for the recurrence of manic symptoms, for which the rate was higher in people who received lamotrigine than people treated with lithium., Harms: the rate of adverse events associated with lamotrigine was lower than that of lithium., Certainty of the evidence, We assessed the certainty of our included evidence to be very low to moderate. This is because majority of the included trials did not describe how treatment allocation was concealed. Given that we were unable to identify high‐confidence evidence the overall findings of this systematic review should be interpreted carefully., Conclusions, Lamotrigine may be superior to placebo in efficacy and may be comparable in safety. And then, lamotrigine was as effective as lithium except for its recurrence rate of mania, and was superior to lithium in terms of safety. Future studies in this field with robust methods and transparent reporting are needed to confirm our results and to fully answer our pre‐specified review question.
Causes and Natural Treatments for Bipolar Disorder | A Guide to Alternative Mental Health
Causes and Natural Treatments for Bipolar Disorder
Integrative Therapies for Bipolar Disorder
Medication and psychotherapy are the primary treatments for bipolar disorder, but many who are living with the condition are interested in integrative therapies, too.

My Recovery: The Treatment That Changed My Life
For the last year, i have been successfully off of lithium. Lithium was the only medication I was taking. I have dealt with a severe form of manic depression all of my life, I was suicidal for years. My bipolar was so bad that i couldn't even think straight at all. i lived in constant fear and i have a very vague memory of my life. I realize what I have done may not help everyone who suffers from similar mental problems but it helped/worked for me. What changed things around for me was reading...

Psilocybin Treatment for Major Depression Effective for Up to a Year for Most Patients, Study Shows
Previous studies by Johns Hopkins Medicine researchers showed that psychedelic treatment with psilocybin relieved major depressive disorder symptoms in adults for up to a month. Now, in a follow-up study of those participants, the researchers report that the substantial antidepressant effects of psilocybin-assisted therapy, given with supportive psychotherapy, may last at least a year for some patients.

Occurrence of Psychosis and Bipolar Disorder in Individuals With ADHD Treated With Stimulants
This systematic review and meta-analysis evaluates the association between psychosis or bipolar disorder and stimulant treatment among individuals with attention-deficit/hyperactivity disorder.

‘I don’t know who I am without it’: the truth about long-term antidepressant use
Prescriptions have doubled in a decade, but very little is known about the effect of taking SSRIs for years. Is it a lifesaver or a happiness trap?

Aniracetam... holy crap does it work!
For those familiar with Piracetam.. Aniracetam is another nootropic that is supposed to be more effective at lower dosages, and they're correct - it's effective. I took 2.6g of it about 3 hours...
Antidepressants rapidly alter brain architecture, study finds
A single dose of a popular class of psychiatric drug used to treat depression can alter the brain’s architecture within hours, even though most patients usually don’t report improvement for weeks, a new study suggests.
ADHD Medications Improve Long-Term Cognitive Function - Neuroscience News
Long-term treatment with both stimulant (Methylphenidate) and non-stimulant (Atomoxetine) medications significantly improves cognitive functions in individuals with ADHD.

Johns Hopkins Study Finds Psilocybin's Ideal Dose For Long-Term Positive Effects | Minds
Groundbreaking research at Johns Hopkins University of Medicine has provided insight into the benefits of mediated doses of psilocyben, the ...
Translational Significance of Selective Estrogen Receptor Modulators in Psychiatric Disorders
Accumulating data from various clinical trial studies suggests that adjuvant therapy with ovarian hormones (estrogens) could be effective in reducing cognitive deficit and psychopathological symptoms in women with psychiatric disorders. However, estrogen therapy poses serious limitations and health issues including feminization in men and increased risks of thromboembolism, hot flashes, breast hyperplasia, and endometrium hyperplasia when used for longer duration in older women (aged ≥ 60 years) or in women who have genetic predispositions. On the other hand, selective estrogen receptor modulators (SERMs), which may (or may not) carry some risks of hot flashes, thromboembolism, breast hyperplasia, and endometrial hyperplasia, are generally devoid of feminization effect. In clinical trial studies, adjuvant therapy with tamoxifen, a triphenylethylene class of SERM, has been found to reduce the frequency of manic episodes in patients with bipolar disorder, whereas addition of raloxifene, a benzothiophene class of SERM, to regular doses of antipsychotic drugs has been found to reduce cognitive deficit and psychological symptoms in men and women with schizophrenia, including women with treatment refractory psychosis. These outcomes together with potent neurocognitive, neuroprotective, and cardiometabolic properties suggest that SERMs could be the potential targets for designing effective and safer therapies for psychiatric disorders.

Magnesium and the Brain: The Original Chill Pill
Magnesium is an old home remedy for all that ails you, including "anxiety, apathy, depression, headaches, insecurity, irritability, restlessness, talkativeness, and sulkiness."

Psilocybin for major depression granted Breakthrough Therapy by FDA
The US Food and Drug Administration (FDA) has granted psilocybin therapy a Breakthrough Therapy designation for the second time in a year, this time with a view on accelerating trials testing its efficacy treating major depressive disorder (MDD).

Methylphenidate and the risk of psychosis in adolescents and young adults: a population-based cohort study
Background There is a clinical concern that prescribing methylphenidate, the most common pharmacological treatment for attention-deficit hyperactivity disorder (ADHD), might increase the risk of psychotic events, particularly in young people with a history of psychosis. We aimed to determine whether the risk of psychotic events increases immediately after initiation of methylphenidate treatment or, in the longer term, 1 year after treatment initiation in adolescents and young adults with and without a previously diagnosed psychotic disorder. Methods In this cohort study, we used population-based observational data from the Swedish Prescribed Drug Register, the National Patient Register, and the Total Population Register, three population-based registers containing data on all individuals in Sweden, to attain data on sex, birth, death, migration, medication use, and psychotic events for all eligible participants. We screened individuals on these registers to identify those receiving methylphenidate treatment, and who were aged 12–30 years at the start of treatment, for their inclusion in the study. We used a within-individual design to compare the incidence of psychotic events in these individuals during the 12-week periods immediately before and after methylphenidate initiation. Longer term risk was assessed by comparing the incidence of psychotic events 12 weeks before methylphenidate initiation and during a 12-week period one calendar year before the initiation of methylphenidate with the incidence of these events during the 12-week period one calendar year after methylphenidate initiation. We estimated the incidence rate ratios (IRR) and 95% CIs of psychotic events after the initation of methylphenidate treatment, relative to the events before treatment, which were defined as any hospital visit (inpatient admission or outpatient attendance, based on data from the National Patient Register) because of psychosis, using the International Classification of Diseases version 10 definition. Analyses were stratified by whether the individual had a history of psychosis. Findings We searched the Swedish Prescribed Drug Register to find eligible individuals who had received methylphenidate between Jan 1, 2007 and June 30, 2012. 61 814 individuals were screened, of whom 23 898 (38·7%) individuals were assessed and 37 916 (61·3%) were excluded from the study because they were outside of the age criteria at the start of treatment, they had immigrated, emigrated, or died during the study period, or because they were administered other ADHD medications. The median age at methylphenidate initiation was 17 years, and a history of psychosis was reported in 479 (2·0%) participants. The IRR of psychotic events in the 12-week period after initiation of methylphenidate treatment relative to that in the 12-week period before treatment start was 1·04 (95% CI 0·80–1·34) in adolescents and young adults without a history of psychosis and 0·95 (0·69–1·30) among those with a history of psychosis. Interpretation Contrary to clinical concerns, we found no evidence that initiation of methylphenidate treatment increases the risk of psychotic events in adolescents and young adults, including in those individuals with a history of psychosis. Our study should reassure clinicians considering initiating methylphenidate treatment for ADHD in adolescents and young adults, and it challenges the widely held view in clinical practice that methylphenidate should be avoided, or its use restricted, in individuals with a history of psychosis. Funding Swedish Research Council, National Institute of Mental Health, UK National Institute of Health Research Nottingham Biomedical Research Centre.
The Yale Manual for Psilocybin-Assisted Therapy of Depression (using Acceptance and Commitment Therapy as a Therapeutic Frame)
The Yale Manual for Psilocybin-Assisted Therapy of Depression provides researchers and therapists with methods, structure, and areas to consider regarding the use of psychedelic- assisted therapy in the treatment of Major Depressive Disorder (MDD). In particular, this manual illustrates a mode of utilizing Acceptance and Commitment Therapy (ACT) as a therapeutic framework for psilocybin-assisted therapy of depression.
New Ketamine study 🧪. Abstract: ✅Ketamine "tablets were effective, safe & well tolerated" Actual results: ❌At primary endpoint of 13 weeks, 0 of 4 ketamine groups outperformed placebo /re remission ❌At 13 weeks, only 1 of 4 outperformed placebo /re response, with a beautiful p-value of 0.046 🤪
Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial - Nature Medicine
www.nature.com